Reslizumab is a humanized monoclonal IL-5 antibody developed by Teva Pharmaceuticals that has been approved in the USA for patients aged ≥18 years as add-on maintenance treatment for severe asthma with an eosinophilic phenotype [130]. This evidence concerns the gene IL5 and asthma.